Clinical Trials Browser

Interventional × Lung Neoplasms × aflutinib × Clear all

NCT07185997 2026-05-11

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT04671303 2025-05-11

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Phase 2 Completed

Lung Neoplasms

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms